- ￥289 - 3180
- TargetMol
- 美国
- T6230
- 2025年07月14日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
零下80~20°C
- 保质期：
Powder: -20°C for 3 years In solvent: -80°C for 2 years
- 英文名：
Imatinib
- 库存：
10
- 供应商：
TargetMol
- CAS号：
152459-95-5
- 规格：
1 mL/200 mg/1 g/500 mg/100 mg/5 g
| 规格： | 1 mL | 产品价格： | ￥455.0 |
|---|---|---|---|
| 规格： | 200 mg | 产品价格： | ￥413.0 |
| 规格： | 1 g | 产品价格： | ￥1260.0 |
| 规格： | 500 mg | 产品价格： | ￥747.0 |
| 规格： | 100 mg | 产品价格： | ￥289.0 |
| 规格： | 5 g | 产品价格： | ￥3180.0 |
Product Introduction
Bioactivity
英文名:Imatinib
描述:Imatinib (STI571) is a multi-targeted receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of BCR/ABL, v-Abl, PDGFR, and c-kit with oral activity. Imatinib has antitumor activity for the treatment of chronic granulocytic leukemia.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Detection of BCR-ABL Mutations and Resistance to Imatinib Mesylate
The major mechanism of imatinib resistance for patients with chronic myeloid leukemia (CML) is clonal expansion of leukemic cells with mutations in the Bcr-Abl fusion tyrosine kinase that reduce the capacity of imatinib to inhibit kinase
and quantitate the tumor-specific BCR-ABL1 RNA have been shown to be an ultrasensitive diagnostic, prognostic, and monitoring tool for Philadelphia-positive leukemias. A novel tyrosine kinase inhibitor (TKI), imatinib, has been confirmed as an effective targeted
RNAi. Here we show that in vivo application of targeted nonvirally delivered synthetic bcr-abl siRNA in a female patient with recurrent Philadelphia chromosome positive chronic myeloid leukemia (CML) resistant to imatinib (Y253F mutation
技术资料暂无技术资料 索取技术资料
